Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

News SummaryMost relevantAll newsSector news 

EMA Starts Review of Tredaptive, Pelzont, Trevaclyn Medicines

12/21/2012 | 05:46am US/Eastern

LONDON--The European Medicines Agency, or EMA, Friday said it has started a review of the safety and efficacy of Tredaptive, Pelzont and Trevaclyn, identical medicines that are used to treat adults with dyslipidaemia, particularly combined mixed dyslipidaemia and primary hypercholesterolaemia.


-Review was triggered because the Agency was informed by the pharmaceutical company Merck, Sharp & Dohme of the preliminary results of a large, long-term study comparing the clinical effects of adding these medicines to statins (standard medicines used to reduce cholesterol) with statin treatment alone.

-Study raises questions about the efficacy of the medicine when added to statins, as this did not reduce the risk of major vascular events compared with statin therapy alone.

-Preliminary results saw a higher frequency of non-fatal but serious side effects in patients taking the medicines than in patients only taking statins.

-Pharmacovigilance Risk Assessment Committee (>> PRODUCTIVITY TECHS CORP) will assess the data and make a recommendation to the Committee on Medicinal Products for Human Use (>> Champion Industries, Inc.), which will issue an opinion on the regulatory action required.

-Opinion is expected in January 2013.

-Write to Tapan Panchal at tapan.panchal@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : PRODUCTIVITY TECHS CORP, Champion Industries, Inc.
React to this article
Latest news on MERCK & CO., INC.
11/25 MERCK : Researchers from Merck & Company Detail Findings in Type 2 Diabetes [Saf..
11/25 MERCK : Study Results from Merck & Company Broaden Understanding of HIV/AIDS (Me..
11/25 ELI LILLY : Lilly and Merck Expand Immuno-oncology Collaboration with Phase III ..
11/24 MERCK : Announces Increased Quarterly Dividend
11/23 Pfizer-Allergan to take healthcare M&A deals to above $600 billion in 2015
11/23 Timeline - Saunders gets key job as Pfizer, Allergan combine
11/23 Pfizer set to buy Allergan for more than $150 bln
11/23 MERCK : MoH ups war on counterfeit drugs
11/21 MERCK : Announces Initial Results for KEYTRUDA® (pembrolizumab) with Novel Immun..
11/20DJCelldex Vaccine Rindopepimut Cuts Death Risk From Brain Cancer, Study Shows
News chart
Full-screen chart
Income Statement Evolution
More Financials